Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | MAP3K5 | Q99683 | 9/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.33 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7473861 | 0.87 | ABL1 (0.35) | ADORA1MAP3K5CNR1LMNAMCL1 | |
| SCHEMBL7477975 | 0.85 | MAP3K5 (0.40) | ADORA1MAP3K5MCL1ALDH1A1KCNK3 | |
| SCHEMBL7473183 | 0.82 | ADORA1 (0.37) | ADORA1MAP3K5CNR1LMNAMCL1 | |
| SCHEMBL7480623 | 0.82 | ADORA1 (0.39) | ADORA1CNR1LMNASMN1; SMN2SCN9A | |
| SCHEMBL7473138 | 0.79 | MAP3K5 (0.36) | ADORA1MAP3K5CNR1MCL1ALDH1A1 | |
| SCHEMBL7479491 | 0.74 | TP53 (0.40) | ADORA1MAP3K5CNR1LMNASMN1; SMN2 | |
| SCHEMBL7480247 | 0.74 | GRIN2B (0.40) | — | |
| SCHEMBL8275667 | 0.69 | NOS1 (0.46) | ADORA1CNR1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL317651 | 0.68 | ADORA1 (0.43) | ADORA1SMN1; SMN2 | |
| SCHEMBL7478159 | 0.68 | MAP3K5 (0.45) | ADORA1MAP3K5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020151572-A1 | PHARMACEUTICAL USES FOR NOS INHIBITORS | LOWE JOHN A (US) | 2002-10-17 | — | — | US | disclosed |
| EP-1007512-B1 | BRANCHED ALKOXY-SUBSITUTED 2-AMINOPYRIDINES AS NOS INHIBITORS | PFIZER PROD INC (US) | 2002-04-03 | — | — | EP | disclosed |
| US-6362195-B1 | INHIBITOR OF NITRIC OXIDE SYNTHASE; CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2002-03-26 | — | — | US | disclosed |
| US-20020022642-A1 | Branched alkoxy-subsituted 2-aminopyridines | LOWE JOHN ADAMS (US) | 2002-02-21 | — | — | US | disclosed |
| EP-1109556-A2 | NEW PHARMACEUTICAL USES FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
| EP-1007512-A1 | BRANCHED ALKOXY-SUBSITUTED 2-AMINOPYRIDINES AS NOS INHIBITORS | Pfizer Products Inc. (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-2000009130-A2 | NEW PHARMACEUTICAL USES FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| WO-1999011620-A1 | BRANCHED ALKOXY-SUBSITUTED 2-AMINOPYRIDINES AS NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022642-A1 | Branched alkoxy-subsituted 2-aminopyridines | NOS3, NOS2, PNMT | ADORA1 196/4885MAP3K5 1197/4885CNR1 214/4885 |
| US-20020151572-A1 | PHARMACEUTICAL USES FOR NOS INHIBITORS | NOS1, NOS3, NOS2 | ADORA1 857/4885MAP3K5 1935/4885CNR1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.